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(SM-BOSS): a prospective randomized trial
comparing laparoscopic sleeve gastrectomy and
Roux-en-Y gastric bypass. Ann Surg. 2013;258:
690–694. discussion 695.
3. Brethauer SA, Kim J, el Chaar M, et al. Stand-
ardized outcomes reporting in metabolic and bari-
atric surgery. Surg Obes Relat Dis. 2015;11:
489–506.
Response to: ‘‘Are
Guidelines for
Standardized Outcome
Reporting in Bariatric
Surgery Responsible
for Missing the Big Picture
in Bariatric Surgery
Related Major
Complications?’’
Reply:
We thank Fysekidis et al
1 for their
important comments on the general
concept of reporting bariatric outcomes.
Ideal complication reporting in surgery has
been a matter of debate for a long time. In
bariatric surgery, it is even more complex as
the main outcome of obesity treatment is not
only weight loss but a combination of weight
loss, reduction in comorbidity and mortality,
increase of quality of life, and complications.
The BAROS score intended to implement
these factors in a scoring system that never
really gained wide acceptance.
Fysekidis et al1 challenge in their letter
to the editor our interpretations of the 3-year
results of the ‘‘Swiss Multicentre Bypass or
Sleeve Study’’ (SM-BOSS) on BAROS score
regarding equal effectiveness in terms of
weight loss and complication rate.2
We would like to respond to the
specific questions/remarks as follows:
(i) Dilution of number of complications: It
is widely accepted in the surgical liter-
ature to differ between early (<30 days)
and late morbidity (>30 days). The
current article covers an interim
analysis of the SM-BOSS trial. Thus,
it is too early to draw final conclusions
on which of the 2 operations, bypass or
sleeve, is safer. A combination of early
and late morbidity will have to be ana-
lyzed when all patients have reached the
5-year follow up.
(ii) Correct sample size for PRT: It is much
easier to have a large enough sample
size for comparison of continuous vari-
ables such as weight loss. To compare
the prevalence of complications
between 2 surgical treatment arms, a
large number of patients in each group
would be necessary to gain enough
power. This is especially true for bari-
atric surgery which in general has a very
low complication rate. The acceptance
rate for patients to be randomly
assigned to 2 surgical procedures that
are anatomically quite different was in
our trial approximately 5%. Swiss
patients often have a firm idea on the
type of operation they prefer and it was
challenging to convince them to accept
randomization. SM-BOSS is the largest
PRT up to today comparing early and
mid-term results of sleeve and bypass
but there are larger studies recruiting
presently, for example, the ‘‘Bypass
Equipoise Sleeve Trial’’ in Sweden
(BEST, https://clinicaltrials.gov/ct2/
show/NCT02767505) aiming to recruit
4000 patients. BEST should be better
suited to answer the issue of safety of
the 2 procedures.
(iii) Early morbidity: In the analysis of the
1 year results,3 we presented the data in
Table 2 first by listing major and minor
complications (major ¼ need for inter-
vention/operation and minor ¼ medical
treatment only) and second by quantify-
ing them with the Clavien-Dindo score.4
This scoring system aims to allow com-
parison between groups based on the
therapy necessary to treat the compli-
cation. It also allows comparison
between different trials. Complications
grade III and higher are interpreted as
major as they require a surgical, endo-
scopic, or radiological intervention with
or without general anaesthesia. How-
ever, wewere unable to find a significant
difference in complication rates of grad
III or higher between sleeve (n¼ 1) and
bypass (n ¼ 5).
(iv) Late morbidity: We agree that we did
not quantify the late morbidity similar
to the Clavien-Dindo score in the 3-year
article.5 Till now, no validated score for
late complications exists. However, the
numbers mentioned by Fysekidis et al6
for ‘‘reoperations for major compli-
cations’’ are incorrect. In the sleeve
group, 2 patients had to be converted
to bypass because of severe reflux, and
another 2 were reoperated for insuffi-
cient weight loss as compared with 6
patients in the bypass group that were
reoperated until 3 years postoperation
(internal hernia, bowel obstruction, and
insufficient weight loss). Thus, total
‘‘major’’ complications needing reop-
eration between primary operation until
3 years postoperation, that is, early and
late morbidity together, were 5 in the
sleeve and 11 in the bypass group (4.8%
vs 10%, P ¼ 0.13). Furthermore, the
long-term issue of gastroesophageal
reflux after sleeve has to be taken into
account when discussing the safety of
the 2 procedures. In a recent article by
Genco et al,6 17% of 110 asymptomatic
patients showed signs of Barrett’s
esophagus after a mean of 58 months
postsleeve. In other words, although the
long-term side effects of the bypass
procedures are well documented, as
the first bypass procedures were per-
formed over 50 years ago, we still do
not know all possible side effects of
sleeve gastrectomy yet.
In conclusion: we agreewith Fysekidis
et al1 that early and long-term morbidity have
to be taken into account when judging the
safety of a procedure. So far, the 1- and 3-
year analysis of the SM-BOSS trial show, that
both sleeve and bypass seem equally effec-
tive in terms of weight loss and remission of
comorbidity except for GERD, dyslipidemia
and possibly type 2 diabetes (SM-BOSS is
underpowered for that particular secondary
endpoint). Further, there may be a trend for a
superior safety profile of the sleeve gastrec-
tomy (P ¼ 0.13, underpowered for this end-
point). However, please note that final
conclusions can only be drawn at 5 years’
follow up and longer as there seems to be
better weight loss and a higher rate of type 2
diabetes remission after bypass with longer
follow up.7,8 Future SM-BOSS analyses and
results from other trials will hopefully enable
us to allocate morbidly obese patients to the
optimal bariatric procedure and thus improve
the individual result.
In the meantime, it is reassuring to
know that sleeve gastrectomy is a potent
and safe bariatric operation and can be
offered to selected patients.
Disclosure: The authors declare no
conflicts of interest.
Ralph Peterli, MD
Professor of Surgery, Department of Surgery,
St. Claraspital, Basel, Switzerland
ralph.peterli@claraspital.ch
Bettina K. Wo¨lnerhanssen, MD
Department of Research, St. Claraspital,
Basel, Switzerland
Department of Biomedicine, University
Hospital of Basel, Basel, Switzerland
Annals of Surgery  Volume 268, Number 1, July 2018 Letters to the Editor
 2017 Wolters Kluwer Health, Inc. All rights reserved. www.annalsofsurgery.com | e13
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Marco Bueter, MD, PhD
Department of Visceral and Transplantation
Surgery, University Hospital Zu¨rich, Zu¨rich,
Switzerland
REFERENCES
1. Fysekidis M, Catheline JM. Are Guidelines for
Standardized Outcome Reporting in Bariatric
Surgery Responsible for Missing the Big Picture
in Bariatric Surgery Related Major Complications?
Ann Surg. May 25, 2017 [Epub ahead of print].
2. Oria HE, Moorehead MK. Bariatric analysis and
reporting outcome system (BAROS). Obes Surg.
1998;8:487–499.
3. Peterli R, Borbely Y, Kern B, et al. Early results of
the Swiss Multicentre Bypass or Sleeve Study
(SM-BOSS): a prospective randomized trial com-
paring laparoscopic sleeve gastrectomy and Roux-
en-Y gastric bypass. Ann Surg. 2013;258:690–694.
discussion 695.
4. Dindo D, Demartines N, Clavien PA. Classification
of surgical complications: a new proposal with
evaluation in a cohort of 6336 patients and results
of a survey. Ann Surg. 2004;240:205–213.
5. Peterli R, Wolnerhanssen BK, Vetter D, et al.
Laparoscopic sleeve gastrectomy versus Roux-Y-
gastric bypass for morbid obesity-3-year outcomes
of the prospective randomized Swiss multicenter
bypass or sleeve study (SM-BOSS). Ann Surg.
2017;265:466–473.
6. Genco A, Soricelli E, Casella G, et al. Gastro-
esophageal reflux disease and Barrett’s esophagus
after laparoscopic sleeve gastrectomy: a possible,
underestimated long-term complication. Surg Obes
Relat Dis. 2017;13:568–574 [Epub ahead of print].
7. Zhang Y, Zhao H, Cao Z, et al. A Randomized
Clinical Trial of Laparoscopic Roux-en-Y gastric
bypass and sleeve gastrectomy for the treatment of
morbid obesity in China: a 5-year outcome. Obes
Surg. 2014;24:1617–1624.
8. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric
surgery versus intensivemedical therapy for diabetes -
5-year outcomes. N Engl J Med. 2017;376:641–651.
Letter to the Editor:
Stopping the Bleeding Is
Not Enough
To the Editor:
A s representatives of the American Col-lege of Surgeons Committee on Trauma
(ACS COT), we gratefully provide comment
and context to the Surgical Perspective article
published in your January 2017 issue.1 Drs
Masiakos and Warshaw emphasize the
importance of injury prevention, and we at
the ACS COT could not agree more strongly.
In response and for perspective clarity, we
wish to emphasize that the ACS COT’s
approach to firearm injury is and has been
comprehensive. ACS COT strategy is built on
a trauma system (public health) model aimed
at preventing injuries from occurring (thus
the description of our firearm injury preven-
tion program detailed below); achieving
rapid and effective treatment at the scene
of injury (thus our Stop the Bleed Program
and support for EMS); rapid, definitive, qual-
ity treatment of the injured patient [trauma
center verification review and consultation
(VRC), Trauma Quality Improvement Pro-
gram (TQIP), Performance Improvement and
Patient Safety (PIPS), etc]; and rehabilitation
and reintegration (VRC).
For at least 3 decades, the ACS COT
has advocated for prevention of firearm
injury and death, and also for treatment.
Many of these efforts have stalled because
of a lack of consensus among surgeons (and
the public) regarding how best to proceed.
Most recently, we initiated a concerted and
dedicated effort to achieve consensus around
how best to eliminate unnecessary death and
suffering related to firearm injury.
We began by publishing a description
of our view on a public health approach to
firearm injury prevention and on how consen-
susmight be reached to address this significant
public health challenge in an article entitled
‘‘Firearm injury prevention: A consensus
approach to reducing preventable deaths.’’2
Next, to clearly understand theopinions
of ACS COT members regarding the import-
ance of firearm injury prevention and possible
advocacy initiatives, we conducted a member
survey to help guide injury prevention and
policy efforts, and we hosted a town hall of
our members.3 Our survey response rate was
93%; 88% of respondents believe that the
American College of Surgeons should give
the highest or a high level of priority to
reducing gun injuries; 95% agree that health-
care professionals should be allowed to coun-
sel patients about how to prevent gun-related
injury; 96% agree that federal funds should be
used to fund research on epidemiology and
prevention of firearm-related injuries.We also
asked COT members to indicate their support
for American College of Surgeons’ advocacy
initiatives regarding 15 potential policy initiat-
ives.4 A brief summary of some of the results
of this survey is listed below:
 Support steps for Congress to appropriate
federal funds to conduct research to better
understand and to prevent firearm injuries
and death (92% support or strongly sup-
port);
 Monitor and advocate for legislation that
enables healthcare professionals to coun-
sel their patients on injury prevention
including firearm safety (90% support or
strongly support);
 Advocate for federal legislation which
provides an increase in funding for mental
health programs (93% support or strongly
support);
 Multiple COT members, through survey
responses and townhall comments, empha-
sized violence as the ‘‘root cause’’ of many
firearm injuries and deaths, and strongly
encouraged the ACS COT to address vio-
lence prevention and intervention.
Based on our underlying philosophy
and the consensus views of our surgeon
members, the ACS COT is moving forward
with the following:
 Approach firearm injury as a medical
problem, not as a political problem;
 Encouraging the development of evi-
dence-based violence prevention pro-
grams. We aim to implement these
programs through our network of 458
ACS verified trauma centers;
 Encouraging healthcare providers to
counsel patients and families on safe stor-
age and other evidence-based prevention
initiatives to decrease firearm injuries;
 Developing and advocating for a research
agenda to better understand the factors
that contribute to firearm injury and death
to develop additional evidence-based pre-
vention programs;
 Continuing to foster a civil, collegial dis-
cussion around how best to eliminate
unnecessary injury, death, and suffering.
‘‘Stop the Bleed’’ (http://www.
bleedingcontrol.org/)—a program intended
to turn bystanders into immediate respond-
ers—is critically important. The Stop the
Bleed program is a well thought out and
logically developed initiative which will
save lives. Although it is not a prevention
program, Stop the Bleed provides a frame-
work for trauma care providers to interact
with communities, and engage the public in
the larger discussion that injury-related
deaths can be prevented.We emphasize, Stop
the Bleed is an integrated component to the
ACS COT strategy aimed at achieving zero
preventable deaths and disability through a
combination of prevention and optimal
care for the injured patient (http://www.
nationalacademies.org/hmd/Reports/2016/
A-National-Trauma-Care-System-Integrating-
Military-and-Civilian-Trauma-Systems.aspx).
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